EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access

Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma

Kathryn Lurain iD, Ramya Ramaswami iD, Irene Ekwede, Vanessa Eulo iD, Gaurav Goyal iD, Manoj Menon iD, Thomas A Odeny iD, Elad Sharon iD, Michael J Wagner iD, Chia-Ching Jackie Wang, Nina Bhardwaj, Philip A Friedlander und 15 weitere

Journal of Clinical Oncology · 2025-02 · 43 (4) · 432-442

DOI: 10.1200/jco.24.00640 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, 2025-02. Verfasst von Kathryn Lurain und 26 weiteren Autor:innen. Beteiligte Einrichtung: HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Sarcoma, Kaposi, HIV Infections, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Cancer Immunotherapy Trials Network 12 demonstrated safety of pembrolizumab in treating advanced cancer in people with HIV. Here, we report results of the Kaposi sarcoma (KS) cohort. METHODS In this multicenter phase I trial, we enrolled participants with HIV-associated KS on antiretroviral therapy with CD4 + ≥50 cells/μL and HIV plasma RNA

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedSarcoma, KaposiHIV InfectionsAntineoplastic Agents, ImmunologicalAIDS-Related Opportunistic InfectionsImmune Checkpoint InhibitorsHumansMaleMiddle AgedAdultAged

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • University of Alabama at Birmingham, Birmingham, AL.
  • Fred Hutchinson Cancer Center and University of Washington, Seattle, WA.
  • Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Dana-Farber Cancer Institute, Boston, MA.
  • University of California San Francisco, San Francisco, CA.

ORCID-Profile: Kathryn Lurain, Ramya Ramaswami, Vanessa Eulo, Gaurav Goyal, Manoj Menon, Thomas A Odeny, Elad Sharon, Michael J Wagner, Maher Abdul-Hay, Elena M Cornejo Castro, Wendell Miley, Judith Kaiser, Robert Yarchoan, Steven P Fling, Thomas S Uldrick

Förderung

  • NCI NIH HHS
  • Intramural NIH HHS

Zitieren

APA

Lurain, K., Ramaswami, R., Ekwede, I., Eulo, V., Goyal, G., Menon, M., Odeny, T. A., Sharon, E., Wagner, M. J., Wang, C. J., Bhardwaj, N., Friedlander, P. A., Abdul-Hay, M., Cornejo Castro, E. M., Labo, N., Marshall, V. A., Miley, W., Moore, K., Roshan, R., …, & Uldrick, T. S. (2025). Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma. Journal of Clinical Oncology, 43(4), 432-442. https://doi.org/10.1200/jco.24.00640

Vancouver

Lurain K, Ramaswami R, Ekwede I, Eulo V, Goyal G, Menon M, et al. Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma. Journal of Clinical Oncology. 2025;43(4):432-442. doi:10.1200/jco.24.00640

BibTeX
@article{Lurain2025,
  author = {Lurain, Kathryn and Ramaswami, Ramya and Ekwede, Irene and Eulo, Vanessa and Goyal, Gaurav and Menon, Manoj and Odeny, Thomas A and Sharon, Elad and Wagner, Michael J and Wang, Chia-Ching Jackie and Bhardwaj, Nina and Friedlander, Philip A and Abdul-Hay, Maher and Cornejo Castro, Elena M and Labo, Nazzarena and Marshall, Vickie Ann and Miley, Wendell and Moore, Kyle and Roshan, Romin and Whitby, Denise and Kask, Angela Shaulov and Kaiser, Judith and Han, Emma and Wright, Anna and Yarchoan, Robert and Fling, Steven P and Uldrick, Thomas S},
  title = {Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {4},
  pages = {432--442},
  doi = {10.1200/jco.24.00640}
}
Kostenlos starten →